Screener
NeoGenomics NEO Reportable Segment — Impairment charges (Note 5)
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by NeoGenomics in its filing.
Tagged under the XBRL concept us-gaap:AssetImpairmentCharges.
The source filing: NeoGenomics’s 10-Q, filed July 28, 2026.
- Filed
- Jul 28, 2026, 4:09 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001077183-26-000059
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Other general and administrative(1) | 48,569 | 52,836 | 97,614 | 103,585 |
| Other research and development(1) | 9,934 | 7,859 | 18,393 | 16,961 |
| Other sales and marketing(1) | 26,666 | 23,217 | 50,142 | 44,927 |
| Impairment charges | — | 20,041 | — | 20,041 |
| Loss from operations | (9,771) | (47,628) | (28,012) | (75,453) |
| Interest income | 1,214 | 2,263 | 2,487 | 5,984 |
| Interest expense | (781) | (933) | (1,379) | (2,551) |
| Other (expense) income | (17) | 482 | (29) | 547 |
Item 1. Financial Statements (unaudited)
FAQ
- What is NeoGenomics's reportable segment — impairment charges (note 5)?
- NeoGenomics (NEO) reported reportable segment — impairment charges (note 5) of $0 in Q2 2026.
- How has NeoGenomics's reportable segment — impairment charges (note 5) changed year-over-year?
- NeoGenomics's reportable segment — impairment charges (note 5) decreased by 100.0% year-over-year, from $20.04M to $0.
- What does reportable segment — impairment charges (note 5) mean?
- This metric tracks specific asset impairment losses recognized by the reportable segment as detailed in the financial notes. It highlights potential risks related to asset valuation and the long-term viability of specific investments or business units.
Ask your AI about NeoGenomics's reportable segment — impairment charges (note 5).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude